Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Convergent structural features of respiratory syncytial virus neutralizing antibodies and plasticity of the site V epitope on prefusion F.
Harshbarger W, Tian S, Wahome N, Balsaraf A, Bhattacharya D, Jiang D, Pandey R, Tungare K, Friedrich K, Mehzabeen N, Biancucci M, Chinchilla-Olszar D, Mallett CP, Huang Y, Wang Z, Bottomley MJ, Malito E, Chandramouli S. Harshbarger W, et al. Among authors: mallett cp. PLoS Pathog. 2020 Nov 2;16(11):e1008943. doi: 10.1371/journal.ppat.1008943. eCollection 2020 Nov. PLoS Pathog. 2020. PMID: 33137810 Free PMC article.
Formulation Design, Optimization and In Vivo Evaluations of an α-Tocopherol-Containing Self-Emulsified Adjuvant System using Inactivated Influenza Vaccine.
Lodaya RN, Kanitkar AP, Friedrich K, Henson D, Yamagata R, Nuti S, Mallett CP, Bertholet S, Amiji MM, O'Hagan DT. Lodaya RN, et al. Among authors: mallett cp. J Control Release. 2019 Dec 28;316:12-21. doi: 10.1016/j.jconrel.2019.10.042. Epub 2019 Oct 31. J Control Release. 2019. PMID: 31678654 Free article.
A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models.
Maruggi G, Mallett CP, Westerbeck JW, Chen T, Lofano G, Friedrich K, Qu L, Sun JT, McAuliffe J, Kanitkar A, Arrildt KT, Wang KF, McBee I, McCoy D, Terry R, Rowles A, Abrahim MA, Ringenberg MA, Gains MJ, Spickler C, Xie X, Zou J, Shi PY, Dutt T, Henao-Tamayo M, Ragan I, Bowen RA, Johnson R, Nuti S, Luisi K, Ulmer JB, Steff AM, Jalah R, Bertholet S, Stokes AH, Yu D. Maruggi G, et al. Among authors: mallett cp. Mol Ther. 2022 May 4;30(5):1897-1912. doi: 10.1016/j.ymthe.2022.01.001. Epub 2022 Jan 3. Mol Ther. 2022. PMID: 34990810 Free PMC article. Clinical Trial.
Structural and computational design of a SARS-CoV-2 spike antigen with improved expression and immunogenicity.
Williams JA, Biancucci M, Lessen L, Tian S, Balsaraf A, Chen L, Chesterman C, Maruggi G, Vandepaer S, Huang Y, Mallett CP, Steff AM, Bottomley MJ, Malito E, Wahome N, Harshbarger WD. Williams JA, et al. Among authors: mallett cp. Sci Adv. 2023 Jun 9;9(23):eadg0330. doi: 10.1126/sciadv.adg0330. Epub 2023 Jun 7. Sci Adv. 2023. PMID: 37285422 Free PMC article.
Chimeric Hemagglutinin-Based Influenza Virus Vaccines Induce Protective Stalk-Specific Humoral Immunity and Cellular Responses in Mice.
Choi A, Bouzya B, Cortés Franco KD, Stadlbauer D, Rajabhathor A, Rouxel RN, Mainil R, Van der Wielen M, Palese P, García-Sastre A, Innis BL, Krammer F, Schotsaert M, Mallett CP, Nachbagauer R. Choi A, et al. Among authors: mallett cp. Immunohorizons. 2019 Apr 1;3(4):133-148. doi: 10.4049/immunohorizons.1900022. Immunohorizons. 2019. PMID: 31032479 Free PMC article.
The RSVPreF3-AS01 vaccine elicits broad neutralization of contemporary and antigenically distant respiratory syncytial virus strains.
Sacconnay L, De Smedt J, Rocha-Perugini V, Ong E, Mascolo R, Atas A, Vanden Abeele C, de Heusch M, De Schrevel N, David MP, Bouzya B, Stobbelaar K, Vanloubbeeck Y, Delputte PL, Mallett CP, Dezutter N, Warter L. Sacconnay L, et al. Among authors: mallett cp. Sci Transl Med. 2023 Aug 23;15(710):eadg6050. doi: 10.1126/scitranslmed.adg6050. Epub 2023 Aug 23. Sci Transl Med. 2023. PMID: 37611082
Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1-2 randomised controlled trial.
Folschweiller N, Vanden Abeele C, Chu L, Van Damme P, García-Sastre A, Krammer F, Nachbagauer R, Palese P, Solórzano A, Bi D, David MP, Friel D, Innis BL, Koch J, Mallett CP, Rouxel RN, Salaun B, Vantomme V, Verheust C, Struyf F. Folschweiller N, et al. Among authors: mallett cp. Lancet Infect Dis. 2022 Jul;22(7):1062-1075. doi: 10.1016/S1473-3099(22)00024-X. Epub 2022 Apr 21. Lancet Infect Dis. 2022. PMID: 35461522 Clinical Trial.
Evaluation of the potential effects of AS03-adjuvanted A(H1N1)pdm09 vaccine administration on the central nervous system of non-primed and A(H1N1)pdm09-primed cotton rats.
Planty C, Mallett CP, Yim K, Blanco JC, Boukhvalova M, March T, van der Most R, Destexhe E. Planty C, et al. Among authors: mallett cp. Hum Vaccin Immunother. 2017 Jan 2;13(1):90-102. doi: 10.1080/21645515.2016.1227518. Epub 2016 Sep 14. Hum Vaccin Immunother. 2017. PMID: 27629482 Free PMC article.
An Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine Is Safe, Immunogenic & Efficacious in the Human Viral Influenza Challenge Model. Serum IgG & Mucosal IgA Are Important Correlates of Protection against Illness Associated with Infection.
Lambkin-Williams R, Gelder C, Broughton R, Mallett CP, Gilbert AS, Mann A, He D, Oxford JS, Burt D. Lambkin-Williams R, et al. Among authors: mallett cp. PLoS One. 2016 Dec 22;11(12):e0163089. doi: 10.1371/journal.pone.0163089. eCollection 2016. PLoS One. 2016. PMID: 28005959 Free PMC article. Clinical Trial.
54 results